Skip to main content

Search Articles

Found 3,023 articles

  • Immutep Receives Constructive Regulatory Feedback

    Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

    • 22 Dec 2023
    • Editor

    Immutep Limited today announces constructive feedback has been received from the Paul-Ehrlich-Institut (“PEI”), a German regulatory authority and part of the Committee for Medicinal Products for Human Use (CHMP), regarding the planned TACTI-004 Phase III trial of eftilagimod alpha (“efti”) for first line treatment of metastatic non-small cell lung cancer (NSCLC).

  • Thermo Fisher Scientific’s PPD Clinical Research B

    Thermo Fisher Scientific’s PPD Clinical Research Business Selected by BARDA to Support Phase II Platform Clinical Trial to Treat Acute Respiratory Distress Syndrome (ARDS)

    • 22 Dec 2023
    • Editor

    The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, has been selected by the Biomedical Advanced Research and Development Authority (BARDA) to implement the first BARDA-supported Phase II platform clinical trial to investigate multiple therapeutic options for the treatment of acute respiratory distress syndrome (ARDS).

  • Merck Provides U.S. Regulatory Update on Gefapixan

    Merck Provides U.S. Regulatory Update on Gefapixant

    • 22 Dec 2023
    • Editor

    Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding Merck’s New Drug Application (NDA) for gefapixant, an investigational, non-narcotic, oral selective P2X3 receptor antagonist, under development for the treatment of refractory chronic cough (RCC) or unexplained chronic cough (UCC) in adults.

  • About Poolbeg Pharma

    About Poolbeg Pharma

    • 21 Dec 2023
    • PharmiWeb Editor

    Poolbeg Pharma plc is committed to the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to fund the development of its robust pipeline of innovative products, thereby driving significant value creation.

  • About Curavit

    About Curavit

    • 21 Dec 2023
    • PharmiWeb Editor

    Curavit represents a significant shift in how clinical trials are conducted, moving towards a more decentralized and digital-first approach, which is crucial for the rapidly evolving landscape of digital therapeutics and healthcare research.

  • About Oxford Nanopore

    About Oxford Nanopore

    • 21 Dec 2023
    • PharmiWeb Editor

    Oxford Nanopore Technologies is a company that specializes in the development of nanopore-based electronic systems for analyzing single molecules, including DNA, RNA, and proteins.

  • About Intravacc

    • 21 Dec 2023
    • PharmiWeb Editor

    Intravacc, a CDMO based at Utrecht Science Park, excels in infectious disease and therapeutic vaccine development. It's renowned for transferring vaccine technologies globally, contributing to 30% of childhood vaccines with its expertise. Intravacc supports vaccine development from concept to clinical studies, serving biotech firms, governments, and NGOs, and utilizes innovative platforms and GMP facilities.

  • About Regeneron

    About Regeneron

    • 21 Dec 2023
    • PharmiWeb Editor

    Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases.

  • About Senzime

    About Senzime

    • 21 Dec 2023
    • PharmiWeb Editor

    Senzime, a Swedish medical device company, offers CE/FDA-cleared monitoring systems, focusing on eliminating anesthesia/respiratory complications. Products like TetraGraph® and ExSpiron® 2Xi monitor neuromuscular/respiratory functions post-surgery. Targeting a SEK 40 billion market, it's listed on Nasdaq Stockholm and OTCQX.

  • About KalVista Pharmaceuticals

    About KalVista Pharmaceuticals

    • 20 Dec 2023
    • Editor

    KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors for diseases with significant unmet need. KalVista is developing sebetralstat as an oral on-demand therapy for HAE and anticipates providing data from the phase 3 KONFIDENT clinical trial in early 2024.

  • Elligo Health Research Announces New CEO

    Elligo Health Research Announces New CEO

    • 20 Dec 2023
    • Editor

    Elligo Health Research®, the largest healthcare-enabling research organization, today announced that Elligo’s Founder and CEO, John Potthoff, Ph.D., transitioned his leadership to COO, Barry Simms. Potthoff will assume the role of Elligo’s Chairman, while Simms’ responsibilities will change to driving strategic direction as CEO — guiding the team and customers to make research as care more accessible for patients everywhere.

  • About Nectin Therapeutics

    About Nectin Therapeutics

    • 19 Dec 2023

    Nectin Therapeutics is a clinical stage biotechnology company devoted to transforming the lives of cancer patients by leveraging unique insights into nectin pathways to develop the next generation of immune oncology (IO) therapies.

  • About Evaxion

    About Evaxion

    • 19 Dec 2023
    • PharmiWeb Editor

    Evaxion Biotech A/S is a pioneering TechBio company based upon its AI platform, AI-Immunology™. Evaxion’s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections.

  • About Asceneuron

    About Asceneuron

    • 19 Dec 2023
    • Editor

    Asceneuron is a clinical stage biotech company focused on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need. The company’s pipeline reflects its ambition and commitment to developing treatments for a wide a range of neurodegenerative diseases including Alzheimer’s and Parkinson’s disease, as well as orphan tauopathies.

  • Industry Veteran Abbas Hussain Appointed as Chair

    Industry Veteran Abbas Hussain Appointed as Chair of Asceneuron

    • 19 Dec 2023
    • Editor

    Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases with its exemplary pipeline of O-GlcNAcase (OGA) inhibitors, is pleased to announce the appointment of Abbas Hussain as new Chair to its Board of Directors.

  • About Vicore

    About Vicore

    • 19 Dec 2023
    • Editor

    Vicore is an innovative clinical-stage pharmaceutical company unlocking the potential of a new class of drugs to stop disease progression and restore function. The company is establishing a portfolio in rare lung diseases including idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH). C21 is a first-in-class orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in a phase 2a study of IPF.

  • Vicore Appoints Leading Respiratory Medicine Devel

    Vicore Appoints Leading Respiratory Medicine Developer Dr. Bertil Lindmark MD, PhD, as Chief Medical Officer

    • 19 Dec 2023
    • Editor

    Vicore Pharma Holding AB (publ), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), today announced that Dr. Bertil Lindmark, will join as Chief Medical Officer.

  • About Immunocore

    About Immunocore

    • 19 Dec 2023
    • PharmiWeb Editor

    Immunocore is a biotechnology company that develops T cell receptor therapies for cancer, infectious and autoimmune diseases. It has a platform called ImmTAC that can target and destroy cancer cells. It also has partnerships with several pharmaceutical companies and foundations to advance its research

  • About Cytomos

    About Cytomos

    • 19 Dec 2023
    • PharmiWeb Editor

    Cytomos is developing AuraCyt™, a groundbreaking cell analysis technology, for biopharmaceutical applications. This technology, based on Cytomos Dielectric Spectroscopy (CDS™), aims to address unmet needs in the biopharma industry, providing innovative solutions for cell analysis. The company has received significant investment and grant funding to advance their technology.

  • About Achilles Therapeutics

    About Achilles Therapeutics

    • 19 Dec 2023
    • PharmiWeb Editor

    Achilles Therapeutics specializes in precision T cell therapies for solid tumors, utilizing AI to identify unique cancer markers for targeted treatment.